首页|鼻渊汤辨证加减治疗慢性鼻-鼻窦炎的药学药理情况研究

鼻渊汤辨证加减治疗慢性鼻-鼻窦炎的药学药理情况研究

扫码查看
目的 分析鼻渊汤辨证加减治疗慢性鼻-鼻窦炎的药学药理情况。方法 选取2022年1月—2022年12月本院收治的108例慢性鼻-鼻窦炎患者,随机将其分为对照组和观察组,每组54例。对照组使用常规西药治疗,观察组在常规西药治疗的基础上使用鼻渊汤辨证加减治疗,对比两组的临床疗效、症状评分、各项血清因子。结果 观察组治疗有效率明显高于对照组(P<0。05);观察组治疗后鼻塞、嗅觉障碍、鼻涕后漏、流涕、头痛头昏等症状积分均低于对照组(P<0。05);观察组治疗后血清TIgE、ECP、IL-6水平均低于对照组(P<0。05)。结论 鼻渊汤辨证加减治疗慢性鼻-鼻窦炎患者的效果显著,能有效抑制免疫炎症反应,减轻鼻黏膜充血水肿及渗出,缓解症状。
Pharmacological Study on Syndrome Differentiation and Modification of Nasosinusitis Relieving Decoction for Chronic Nasal Sinusitis Patients
Objective To explore pharmacological and pharmacological effect of syndrome differentiation and modification of nasosinusitis relieving decoction for chronic sinusitis patients.Methods The paper chose 108 patients with chronic sinusitis in our hospital from January 2022 to December 2022,and divided them into two groups randomly.Control group was treated with routine western medicine,while observation group with syndrome differentiation and modification of nasosinusitis relieving decoction.Clinical effect,symptom scores,and various serum factors between two groups were compared.Results Effective rate of treatment in observation group was significantly higher than control group(P<0.05).After treatment,observation group had lower scores of symptoms including nasal congestion,olfactory dysfunction,nasal leakage,runny nose,headache and dizziness than control group(P<0.05).After treatment,average levels of serum TIgE,ECP,and IL-6 in observation group were lower than control group(P<0.05).Conclusion Syndrome differentiation and modification of nasosinusitis relieving decoction can achieve significant curative effect on patients with chronic rhinosinusitis,can inhibit immune inflammatory reactions,reduce nasal mucosal congestion,edema,and exudation,and alleviate symptoms effectively.

Chronic sinusitisSyndrome differentiation and modification of nasosinusitis relieving decoctionCurative effectPharmaceutical pharmacology

王涛

展开 >

湖北省浠水县中医院,湖北 浠水 438200

慢性鼻-鼻窦炎 鼻渊汤辨证加减 疗效 药学药理

2024

智慧健康

智慧健康

ISSN:
年,卷(期):2024.10(18)